$LFAP .23 LifeApps Digital Media Inc. Engages Trilogy

New Post Public Reply Private Reply Replies (0) Message Board
jstops

[b]$LFAP[/b] .23 LifeApps Digital Media Inc. Engages Trilogy Capital Partners to Lead Financial Communications and Investor Relations Initiatives

Trilogy to Drive Investor Awareness for LifeApps' Unique Product Offerings Geared Toward Sports, Health and Entertainment Enthusiasts on the iPhone, iPad, Kindle and Android Devices

SAN DIEGO, CA -- (Marketwire) -- [b][color=blue]Oct 17, 2012[/color][/b] -- LifeApps Digital Media Inc. (the "Company") (OTCQB: LFAP) (OTCBB: LFAP), an emerging growth company and designer of apps and next-generation social networks for sports, health, fitness and entertainment enthusiasts, today announced the engagement of Trilogy Capital Partners to lead its financial communications and investor relations initiatives.

Trilogy is a New York-based financial communications firm providing strategic positioning and investor relations support for dynamic and fast growing companies. Trilogy's mandate is to drive investor awareness for LifeApps as the company capitalizes on the rising demand for highly interactive digital publications and customized health, sports and entertainment apps on today's latest mobile devices and tablets. Trilogy will aim to generate sustainable market interest in LifeApps, while supporting the organization's commitment to growing revenues, earnings and shareholder value.

"The depth of market experience represented by the Trilogy team, combined with the high-growth focus of LifeApps on the digital mobile and tablet scene, make the timing of this relationship ideal," Robert Gayman, CEO of LifeApps Digital Media Inc. "Together with Trilogy, we intend to use all the communication channels available to disseminate and distribute a robust stream of news and information supporting maximum transparency so we can keep the financial community apprised of our ongoing successes."

Trilogy's responsibilities under the agreement include ongoing contact with prospective institutional and retail investors, as well as the distribution of news, research and information to current LifeApps shareholders and potential investors. Trilogy will also manage outreach and presentations to institutional investors and others in the national and international financial community.

LifeApps recently announced the successful completion of its reverse merger (now trading under the symbol "LFAP") on September 20, 2012, as well as its contemporaneous raise of $1.2 million through a private offering. Freshly capitalized, LifeApps is deploying a series of strategic initiatives to enhance its apps and digital product offerings across numerous mobile phones and tablets including the iPad, iPhone, Kindle Fire and leading Android devices.

About LifeApps Digital Media Inc.

LifeApps Digital Media Inc. (OTCQB: LFAP) (OTCBB: LFAP), an emerging growth company, is a designer of sports, health, fitness and entertainment publications and next-generation social networks. As part of its various product launches, the company is becoming a leading authorized developer, publisher and licensee on Apple iOS - iPhone, iPod touch, and iPad devices. Through LifeApps' multi-sport and fitness offerings, including its latest digital magazine app, YouWorkout, subscribers benefit from the expertise of top-tier sports physicians, performance fitness trainers and professional athletes.

For more information about LifeApps and its latest digital media offerings, please visit: www.youworkout.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles